Drug Trial Radar · NCT07730138
Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer
Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
384
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Apr 15, 2028
Study completion Oct 15, 2028
Sponsor
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Jul 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multinational, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 3 Study to Evaluate the Efficacy and Safety of DWP14012 in Participants with Gastric Ulcer
Conditions
- Gastric Ulcer
Interventions
DWP14012 40mg (Fexuprazan)Drug
DWP14012 40mg(Fexuprazan) + placebo of Lansoprazole
Lansoprazole 30mgDrug
Lansoprazole 30mg + Placebo of DWP14012 40mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative gastric ulcer healing rate confirmed by upper gastrointestinal endoscopy through Week 8Time frame: Week 8
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
RS Cipto Mangunkusumo
Jakarta, Indonesia
The Catholic University of Korea, Incheon St. Mary'S Hospital
Incheon, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.